ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Entry into a Material Definitive Agreement

Item1.01 Entry into a Material Definitive Agreement.

On June6, 2017, Antares Pharma, Inc. (the Company) entered into a
Loan and Security Agreement (the Loan Agreement) with Hercules
Capital, Inc. (Hercules), as a lender and agent for the several
banks and other financial institutions or entities from time to
time party to the Loan Agreement (collectively, the Lenders) for
a term loan of up to $35.0 million (the Term Loan). The proceeds
from the Term Loan will be used for working capital and general
corporate purposes.

The first advance of $25.0 million was funded upon execution of
the Loan Agreement on June6, 2017. Under the terms of the Loan
Agreement, the Company may, but is not obligated to, request one
or more additional advances of at least $5.0 million, not to
exceed $10.0 million in the aggregate, subject to the Company
achieving certain corporate milestones and satisfying customary
conditions. The Company must exercise its option to request
additional advances prior to September30, 2018. The Term Loan
will mature on July1, 2022. Upon repayment of the Term Loan,
either at maturity or earlier, the Company must pay the Lenders a
fee equal to 4.25% of the total original principal amount of all
term loan advances made to the terms of the Loan Agreement.

The Term Loan is secured by substantially all of the Companys
assets, excluding intellectual property. The Term Loan accrues
interest at a calculated prime-based variable rate, currently at
8.50%, with a maximum interest rate of 9.50%. Payments under the
Loan Agreement are interest only until the first principal
payment is due on August1, 2019, provided that the interest only
period may be extended to February1, 2020 if the Company achieves
certain corporate milestones.

to the terms of the Loan Agreement, the Company also granted
Hercules the right to invest $1.0 million in any subsequent
equity financing of the Company on the same terms, conditions and
pricing afforded to other financing participants as long as the
Term Loan is outstanding.

The Loan Agreement contains customary affirmative and restrictive
covenants and representations and warranties, including financial
reporting obligations and limitations on dividends, indebtedness,
liens, collateral, investments, distributions, transfers, mergers
or acquisitions, taxes, corporate changes, deposit accounts, and
subsidiaries. The Loan Agreement also contains other customary
provisions, such as expense reimbursement, non-disclosure
obligations, as well as indemnification rights for the benefit of
the Lenders. Upon the occurrence of an event of default and
following any applicable cure periods, if any, a default interest
rate of an additional 4.00% may be applied to the outstanding
loan balances, and the Lenders may declare all outstanding
obligations immediately due and payable and take such other
actions as set forth in the Loan Agreement.

The foregoing description of the Loan Agreement does not purport
to be complete and is qualified in its entirety by reference to
the Loan Agreement. A copy of the Loan Agreement is filed as
Exhibit 10.1 to this Form 8-K and is incorporated herein by
reference.

Item2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant

The foregoing description in Item1.01 above regarding the Loan
Agreement is incorporated into this Item2.03 by reference. This
description is qualified in its entirety by reference to the full
text of the Loan Agreement, a copy of which is attached as
Exhibit 10.1 to this Form 8-K and incorporated herein by
reference.

Item7.01 Regulation FD Disclosure

A copy of the press release announcing the Term Loan and Loan
Agreement is attached hereto as Exhibit 99.1 and incorporated
herein by reference.

The information disclosed under this Item7.01, including Exhibit
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

About ANTARES PHARMA, INC. (NASDAQ:ATRS)

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.